The SINS trial: A randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma

Trials

Volumn 11, Issue , 2010, Pages

  Ozolins, Mara ^a   Williams, Hywel C ^a   Armstrong, Sarah J ^b   Bath Hextall, Fiona J ^a  

^a Centre of Evidence Based Dermatology   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

ARTICLE; BASAL CELL CARCINOMA; CANCER PAIN; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREAM; DNA POLYMORPHISM; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESTHETIC SURGERY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR REGRESSION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEALTH CARE COST; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY; OINTMENT; PATHOLOGY; PATIENT SATISFACTION; PROSPECTIVE STUDY; RECURRENT DISEASE; SKIN TUMOR; TIME;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GENOTYPE; HEALTH CARE COSTS; HUMANS; MALE; OINTMENTS; PATIENT SATISFACTION; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECURRENCE; RESEARCH DESIGN; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953669704     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-42     Document Type: Article

References (16)

1. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992, 327:1649-1662.
2. Miller SJ. Biology of basal cell carcinoma (part1). J Am Acad Dermatol 1991, 24:1-13. 10.1016/0190-9622(91)70001-I, 1999506.
3. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. Br J Dermatol 1999, 141:415-423. 10.1046/j.1365-2133.1999.03033.x, 10583044.
4. Wallberg P, Skog E. The increasing incidence of basal cell carcinoma. Br J Dermatol 1994, 131:914-915. 10.1111/j.1365-2133.1994.tb08607.x, 7857854.
5. Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R. Trends in incidence of basal cell carcinoma; Additional evidence from a UK-primary care database study. International Journal of Cancer 2007, 121(9):2105-2108.
6. Van Hattem S, Aarts MJ, Louwman WJ, Neumann HA, Coebergh JW, Looman CW, Nijsten T, de Vries E. Increase in basal cell carcinoma incidence steepest in individuals with high socioeconomic status: results of a cancer registry study in The Netherlands. Br J Dermatol 2009, 161(4):840-845. 10.1111/j.1365-2133.2009.09222.x, 19438849.
7. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database of Systematic Reviews 2007, (1):CD003412. DOI: 10.1002/14651858.CD003412.pub2.
8. Roenigk RK, Ratz JL, Bailin PL, Wheeland RG. Trends in the presentation and treatment of basal cell carcinomas. J Dermatol Surg Oncol 1986, 12:860-865.
9. McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma: a possible indicator of differing causes. Arch Dermatol 1997, 133:593-596. 10.1001/archderm.133.5.593, 9158412.
10. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinoma. Arch Dermatol 1999, 135:1177-1183. 10522664, 10.1001/archderm.135.10.1177.
11. McGovern TW, Leffell DJ. Mohs surgery. Arch Dermatol 1999, 135:1255-1259. 10.1001/archderm.135.10.1255, 10522675.
12. Wang I, Bendsoe N, Klinteberg CAF, Enejder AM, Andersson-Engels S, Svanberg S, Svanberg K. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase II clinical trial. Br J Dermatol 2001, 144:832-840. 10.1046/j.1365-2133.2001.04141.x, 11298545.
13. Rowe DE, Carroll RJ, Day CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989, 15:315-328.
14. Thorpe K, Zwarenstein M, Oxman A, Treweek S, Furberg C, Altman D, Tunis S, Bergel E, Harvey I, Magid D. A pragmatic explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J clin Epidemiol 2009, 62:464-475. 10.1016/j.jclinepi.2008.12.011, 19348971.
15. Marks R, Gebauer K, Shumak S, Amies M, Bryden J, Fox TL, Owens ML. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Derm 2001, 44:807-813. 10.1067/mjd.2001.113689, 11312429.
16. Zou GA. Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am J Epidemiol 2004, 159:702-706. 10.1093/aje/kwh090, 15033648.